Total Payments
$2,698
2024 Payments
$94.49
Companies
34
Transactions
173
Medicare Patients
3,458
Medicare Billing
$383,218
Payment Breakdown by Category
Food & Beverage$2,487 (92.2%)
Education$210.52 (7.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,487 | 159 | 92.2% |
| Education | $210.52 | 14 | 7.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $572.49 | 33 | $0 (2022) |
| Genentech USA, Inc. | $309.51 | 21 | $0 (2019) |
| PFIZER INC. | $276.62 | 22 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $177.04 | 11 | $0 (2021) |
| Amgen Inc. | $162.43 | 11 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $110.18 | 8 | $0 (2019) |
| Seattle Genetics, Inc. | $83.76 | 6 | $0 (2019) |
| Lilly USA, LLC | $80.96 | 2 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $79.66 | 5 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $66.24 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $94.49 | 5 | PFIZER INC. ($47.96) |
| 2023 | $101.60 | 6 | PFIZER INC. ($62.58) |
| 2022 | $41.10 | 2 | Daiichi Sankyo Inc. ($23.99) |
| 2021 | $100.27 | 7 | Novartis Pharmaceuticals Corporation ($29.58) |
| 2020 | $157.11 | 10 | Novartis Pharmaceuticals Corporation ($35.12) |
| 2019 | $869.86 | 62 | PFIZER INC. ($141.27) |
| 2018 | $736.45 | 44 | Novartis Pharmaceuticals Corporation ($233.96) |
| 2017 | $596.83 | 37 | Genentech USA, Inc. ($264.44) |
All Payment Transactions
173 individual payment records from CMS Open Payments — Page 6 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/24/2018 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $14.56 | General |
| Category: Oncology | ||||||
| 04/16/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $12.57 | General |
| Category: ONCOLOGY | ||||||
| 03/27/2018 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: ONCOLOGY | ||||||
| 03/20/2018 | Merck Sharp & Dohme Corporation | EMEND (Drug), KEYTRUDA, LYNPARZA | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2018 | Novartis Pharmaceuticals Corporation | AFINITOR (Drug), SANDOSTATIN LAR | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: ONCOLOGY | ||||||
| 03/05/2018 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: BioOncology | ||||||
| 02/20/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: Oncology | ||||||
| 02/13/2018 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $11.73 | General |
| Category: Oncology | ||||||
| 02/06/2018 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $10.54 | General |
| Category: ONCOLOGY | ||||||
| 01/30/2018 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $11.47 | General |
| Category: Oncology | ||||||
| 01/23/2018 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR, VOTRIENT | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2017 | Millennium Pharmaceuticals, Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $13.73 | General |
| Category: Oncology | ||||||
| 11/21/2017 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $10.38 | General |
| Category: Oncology | ||||||
| 11/14/2017 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: Oncology | ||||||
| 11/14/2017 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONFOCUS, FOUNDATIONACT | Food and Beverage | In-kind items and services | $17.47 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2017 | Genentech USA, Inc. | VENCLEXTA (Biological) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: BioOncology | ||||||
| 11/06/2017 | Amgen Inc. | Neulasta (Biological), Vectibix | Food and Beverage | In-kind items and services | $10.68 | General |
| Category: Oncology | ||||||
| 11/02/2017 | AstraZeneca Pharmaceuticals LP | FASLODEX (Drug) | Food and Beverage | In-kind items and services | $33.64 | General |
| Category: Oncology | ||||||
| 10/25/2017 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2017 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2017 | Genentech USA, Inc. | GAZYVA (Biological), Rituxan | Food and Beverage | In-kind items and services | $12.90 | General |
| Category: BioOncology | ||||||
| 10/17/2017 | Genentech USA, Inc. | Avastin (Biological), Alecensa | Food and Beverage | In-kind items and services | $8.67 | General |
| Category: BioOncology | ||||||
| 10/10/2017 | Genentech USA, Inc. | Rituxan (Biological) | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: BioOncology/Immunology | ||||||
| 10/02/2017 | Amgen Inc. | Neulasta (Biological), Vectibix | Food and Beverage | In-kind items and services | $12.91 | General |
| Category: Oncology | ||||||
| 08/15/2017 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $11.16 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 828 | 1,369 | $239,811 | $90,558 |
| 2022 | 9 | 872 | 1,422 | $243,880 | $94,087 |
| 2021 | 6 | 852 | 1,551 | $266,219 | $104,593 |
| 2020 | 8 | 906 | 1,648 | $286,000 | $93,980 |
Total Patients
3,458
Total Services
5,990
Medicare Billing
$383,218
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 324 | 773 | $133,129 | $51,624 | 38.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 233 | 274 | $30,442 | $10,612 | 34.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 73 | 93 | $23,250 | $9,944 | 42.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 49 | 49 | $13,965 | $4,512 | 32.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 35 | 37 | $14,985 | $3,611 | 24.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 35 | 55 | $6,325 | $3,331 | 52.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 29 | $4,756 | $2,473 | 52.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 19 | 19 | $6,859 | $2,348 | 34.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 25 | 25 | $5,050 | $1,388 | 27.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 15 | 15 | $1,050 | $714.32 | 68.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 313 | 713 | $122,636 | $46,958 | 38.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 284 | 351 | $38,961 | $16,241 | 41.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 77 | 98 | $24,500 | $10,692 | 43.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 70 | 70 | $19,950 | $6,483 | 32.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 48 | 106 | $12,190 | $5,643 | 46.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 37 | 38 | $15,390 | $3,533 | 23.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 19 | 19 | $6,859 | $2,680 | 39.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 16 | $2,624 | $1,251 | 47.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 11 | 11 | $770.00 | $606.48 | 78.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 413 | 996 | $171,312 | $69,674 | 40.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 233 | 268 | $29,748 | $11,895 | 40.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 55 | 127 | $14,605 | $6,911 | 47.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 53 | 57 | $22,914 | $5,645 | 24.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 54 | 54 | $15,390 | $5,298 | 34.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 44 | 49 | $12,250 | $5,170 | 42.2% |
About Dr. David Close, MD
Dr. David Close, MD is a Medical Oncology healthcare provider based in Lubbock, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1326002130.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Close, MD has received a total of $2,698 in payments from pharmaceutical and medical device companies, with $94.49 received in 2024. These payments were reported across 173 transactions from 34 companies. The most common payment nature is "Food and Beverage" ($2,487).
As a Medicare-enrolled provider, Close has provided services to 3,458 Medicare beneficiaries, totaling 5,990 services with total Medicare billing of $383,218. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Lubbock, TX
- Active Since 04/17/2006
- Last Updated 07/22/2008
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1326002130
Products in Payments
- MEKINIST (Drug) $199.22
- GAZYVA (Biological) $180.11
- TASIGNA (Drug) $143.34
- AFINITOR (Drug) $97.50
- Kyprolis (Biological) $88.17
- XTANDI (Drug) $84.15
- ADCETRIS (Biological) $84.06
- NINLARO (Drug) $79.97
- EMPLICITI (Biological) $67.29
- BOSULIF (Drug) $64.84
- VYXEOS (Drug) $64.62
- IMFINZI (Drug) $55.07
- PROMACTA (Drug) $49.26
- Neulasta (Biological) $49.19
- PADCEV (Biological) $49.05
- KEYTRUDA (Biological) $46.24
- Avastin (Biological) $45.75
- CALQUENCE (Drug) $41.59
- Lenvima (Drug) $39.40
- Epkinly (Drug) $39.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.